FDA: Two diabetes drugs may be linked to heart failure risk

April 5, 2016 by Steven Reinberg, Healthday Reporter

(HealthDay)—Diabetes drugs containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, U.S. health officials warned Tuesday.

Drugs containing these ingredients are Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin extended release), Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone), the U.S. Food and Drug Administration said.

People with type 2 diabetes who use these drugs should not stop taking them without consulting with their doctor, the FDA said.

The agency added that patients on these drugs should contact their doctor if they develop signs and symptoms of , including:

  • Unusual shortness of breath during daily activities.
  • Difficulty breathing when lying down.
  • Tiredness, weakness or fatigue.
  • Weight gain with swelling of the ankles, feet, legs or stomach.

The FDA said it's adding new warnings to the labels about these safety concerns.

Both saxagliptin and alogliptin are in a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, which along with diet and exercise are used to try to lower in adults with type 2 diabetes.

The FDA said its warning was based on results of two large trials done involving patients with heart disease. Both trials found that more patients taking drugs containing saxagliptin or alogliptin were hospitalized for heart failure than patients receiving a placebo.

In the saxagliptin trial, 3.5 percent of patients receiving the drug were hospitalized for heart failure, compared with 2.8 percent of patients receiving a placebo. This means that 35 out of every 1,000 patients taking the drug were hospitalized for heart failure, compared with 28 out of every 1,000 patients not taking it. Risk factors included a history of heart failure or kidney impairment, the FDA reported.

In the alogliptin trial, 3.9 percent of patients taking the drug were hospitalized for heart failure, compared with 3.3 percent receiving a placebo. That's the same as 39 out of every 1,000 patients, compared with 33 out of every 1,000 patients, the agency said.

The FDA said it's asking doctors to consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure. If blood sugar is not well-controlled with current treatments, other diabetes drugs may be needed, the agency said.

Dr. Minisha Sood is director of inpatient diabetes at Lenox Hill Hospital in New York City. She said: "At this time, it is unclear whether this is a 'class effect' which applies to all drugs in the DPP-4 inhibitor category or only saxagliptin and alogliptin. It also remains unclear at this time whether this advice applies to patients at relatively low risk for ."

Sood said there's some research indicating that DPP-4 inhibitors actually reduce cardiovascular problems in some patients. "So, the ultimate effect of this drug class on cardiac events remains to be seen and further study is needed," she said.

This class of drugs "remains a good option for many with diabetes given that they are oral medications with largely tolerable side effects and they effectively reduce glucose levels," Sood said.

Patients should discuss any symptoms or side effects with their before changing medications, she added.

Explore further: Impact of T2DM meds on heart failure hospitalization explored

More information: For more on type 2 diabetes, visit the American Diabetes Association.

Related Stories

Impact of T2DM meds on heart failure hospitalization explored

January 19, 2016
(HealthDay)—For patients with type 2 diabetes, there is no association between hospitalization for heart failure and treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) versus sulfonylureas (SUs) or treatment with ...

Diabetes drug shown not to increase heart failure risk

March 13, 2015
People with the most common form of diabetes can take the new drug Alogliptin without concern for an increased risk of heart failure or cardiovascular disease, according to research by a UConn cardiologist just published ...

FDA approves 3 new drugs for type 2 diabetes

January 26, 2013
(HealthDay)—The U.S. Food and Drug Administration late Friday approved three new medications to help people battle type 2 diabetes.

No increased heart failure with incretin-based drugs

March 24, 2016
Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a ...

FDA to investigate diabetes drug saxagliptin for possible heart failure risk

February 11, 2014
(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it will investigate possible links between the diabetes drug saxagliptin and a heightened risk for heart failure among users.

Saxagliptin not linked to increased fracture risk in T2DM

September 25, 2015
(HealthDay)—For patients with type 2 diabetes, treatment with saxagliptin is not associated with increased fracture risk, according to a study published online Sept. 10 in Diabetes Care.

Recommended for you

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

Proteome of the human heart mapped for the first time

November 15, 2017
A healthy heart beats about two billion times during a lifetime, thanks to the interplay of more than 10,000 proteins. Researchers from the Max Planck Institute of Biochemistry (MPIB) and the German Heart Centre at the Technical ...

First transcatheter implant for diastolic heart failure successful

November 15, 2017
Results presented today at the American Heart Association Scientific Sessions and published in Circulation show that a new device designed to treat diastolic heart failure is safe and effective. The first patient in the randomized, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.